Serina Therapeutics Inc (SER) Stock Price, Quote & News

Company Profile

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which...

Industry: Biotechnology

Sector: Healthcare

Phone: 256 327 9630

Website: serinatherapeutics.com

Address:

601 Genome Way, Suite 2001, Huntsville, United States

littleimagination Jun. 18 at 3:31 PM

$SER Still long SER and Wff, a newer low float Chinese ipo.

0 · Reply

jheerdink Jun. 10 at 6:34 PM

$SER $PFE https://finance.yahoo.com/news/registration-now-open-tribe-public-200500498.html

0 · Reply

jheerdink Jun. 9 at 8:20 PM

$SER Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?" Featuring Serina Therapeutics’ CEO - Wednesday, June 11, 2025 -Entering year 5 of a biotech bear market, approximately 25% of the 700 – 800 publicly traded US biotech companies have negative enterprise values -Recognize the patterns that can lead to strong investment returns Meet with Serina’s CEO Steven A. Ledger Register at Smartest-Bet.TribePublic.com https://investors.serinatherapeutics.com/news/news-details/2025/Registration-Is-Now-Open-For-Tribe-Publics-CEO-Presentation-and-QA-Webinar-Event-Is-the-Beaten-Down-Biotech-Sector-the-Smartest-Bet-in-Todays-Volatile-Market/default.aspx

0 · Reply

jheerdink Jun. 4 at 6:22 PM

$SER Serina Therapeutics Strategically Adds Karuna Therapeutics’ CMO Dr. Stephen Brannan: A Power Move for CNS Innovation & Beyond ( $TAK $LLY ) https://vistapglobal.com/serina-therapeutics-strategically-adds-karuna-therapeutics-cmo-dr-stephen-brannan-a-power-move-for-cns-innovation-beyond-ser-bmy-tak-nvs-lly/ #

0 · Reply

littleimagination May. 16 at 12:44 PM

$SER Hold on tight to SER. Don't let them steal your shares for under $150.

0 · Reply

littleimagination May. 16 at 12:41 PM

$SER $ 3. dollar gap up. This is the type of stock that could follow RGC to 500!

0 · Reply

jheerdink May. 14 at 3:46 AM

$SER "We are energized by the substantial progress and strengthened foundation we've achieved in recent months. Our partnership with Enable Injections, combined with our proprietary POZ optimization technology, continues to advance SER-252 toward a differentiated product profile and potential best-in-class therapy for advanced Parkinson’s care. With new capital infusions in the first quarter and April from strategic investors, we remain focused on reaching key milestones, including dosing the first patient in our Phase 1b clinical trial by the fourth quarter of this year," said Steve Ledger, CEO of Serina Therapeutics. "Importantly, we are dedicated to expanding the impact of our POZ Platform and remain committed to pushing the boundaries of our platform’s potential, from neurological disorders to RNA-based and ADC therapeutics, to improve patient outcomes and quality of life." $PFE https://finance.yahoo.com/news/serina-therapeutics-reports-first-quarter-202300846.html

0 · Reply

Stangman88 May. 9 at 11:56 PM

$SER

0 · Reply

jheerdink Apr. 25 at 5:18 PM

$SER Serina Therapeutics - Enable Injections Presents Survey Results Highlighting Missed Opportunities in Subcutaneous Oncology Drug Development at AACR 2025 https://investors.serinatherapeutics.com/news/news-details/2025/Enable-Injections-Presents-Survey-Results-Highlighting-Missed-Opportunities-in-Subcutaneous-Oncology-Drug-Development-at-AACR-2025/default.aspx

0 · Reply

kshonstocks Apr. 24 at 2:48 PM

$SER 200 dma b/o from scans

0 · Reply

Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025

Jun 17, 2025, 8:30 PM EDT - 7 days ago

UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42

Jun 17, 2025, 6:00 AM EDT - 8 days ago

Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42

Jun 9, 2025, 4:05 PM EDT - 15 days ago

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?"

May 22, 2025, 4:50 PM EDT - 4 weeks ago

Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

May 14, 2025, 3:15 PM EDT - 5 weeks ago

Serina Therapeutics Makes Grants to New Employees Under Inducement Plan

May 8, 2025, 4:23 PM EDT - 6 weeks ago

Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

Apr 29, 2025, 6:00 AM EDT - 2 months ago

Serina Therapeutics to Present at JonesResearch Virtual CNS Day

Apr 15, 2025, 6:30 AM EDT - 2 months ago

Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit

Apr 8, 2025, 4:30 PM EDT - 2 months ago

Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease

Apr 7, 2025, 6:30 AM EDT - 2 months ago

Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

Mar 24, 2025, 4:30 PM EDT - 3 months ago

Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Mar 24, 2025, 6:30 AM EDT - 3 months ago

Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting

Feb 12, 2025, 4:15 PM EST - 4 months ago

Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

Feb 3, 2025, 4:30 PM EST - 5 months ago

Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Jan 15, 2025, 4:05 PM EST - 5 months ago

Serina Therapeutics Announces Sale of UniverXome Subsidiary

Jan 14, 2025, 5:25 PM EST - 5 months ago

Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors

Dec 16, 2024, 6:00 AM EST - 6 months ago

Serina Therapeutics to Present at Tribe Public's Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024

Dec 11, 2024, 6:05 AM EST - 7 months ago

Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit

Dec 2, 2024, 5:22 PM EST - 7 months ago

Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Nov 12, 2024, 5:00 PM EST - 8 months ago

Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Sep 4, 2024, 6:42 PM EDT - 10 months ago

Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 9, 2024, 4:15 PM EDT - 11 months ago

Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Jul 29, 2024, 8:30 AM EDT - 11 months ago

Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit

Jul 18, 2024, 5:00 PM EDT - 1 year ago

Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation

May 14, 2024, 4:05 PM EDT - 1 year ago

Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

Apr 17, 2024, 4:05 PM EDT - 1 year ago

Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman

Mar 26, 2024, 5:04 PM EDT - 1 year ago

Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics

Mar 22, 2024, 5:27 PM EDT - 1 year ago

AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results

Feb 27, 2024, 3:19 PM EST - 1 year ago

AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc. - AGE

Nov 14, 2023, 4:05 PM EST - 1 year ago

AgeX Therapeutics Reports Third Quarter 2023 Financial Results

Aug 30, 2023, 7:00 AM EDT - 1 year ago

Serina Therapeutics and AgeX Therapeutics Enter into Merger Agreement

Aug 14, 2023, 4:05 PM EDT - 2 years ago

AgeX Therapeutics Reports Second Quarter 2023 Financial Results

Jul 24, 2023, 6:28 PM EDT - 2 years ago

AgeX Therapeutics Closes $36,000,000 Debt Exchange for Preferred Stock

Jul 21, 2023, 5:32 PM EDT - 2 years ago

AgeX Therapeutics Announces $36,000,000 Debt Exchange for Preferred Stock

May 23, 2023, 4:05 PM EDT - 2 years ago

AgeX Therapeutics Announces Appeal of NYSE American Determination

May 17, 2023, 5:31 PM EDT - 2 years ago

CORRECTING and REPLACING NYSE American to Commence Delisting Proceedings Against AgeX Therapeutics, Inc. (AGE)

May 17, 2023, 4:34 PM EDT - 2 years ago

NYSE American to Suspend Trading Immediately in AgeX Therapeutics, Inc. (AGE) and Commence Delisting Proceedings

May 12, 2023, 4:05 PM EDT - 2 years ago

AgeX Therapeutics Reports First Quarter 2023 Financial Results

Apr 26, 2023, 4:05 PM EDT - 2 years ago

AgeX Therapeutics Receives Stock Exchange Deficiency Letter

Mar 31, 2023, 4:05 PM EDT - 2 years ago

AgeX Therapeutics Reports Fourth Quarter and Annual 2022 Financial Results

Nov 25, 2022, 3:41 PM EST - 2 years ago

AgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

Nov 10, 2022, 4:05 PM EST - 2 years ago

AgeX Therapeutics Reports Third Quarter 2022 Financial Results

Aug 12, 2022, 4:05 PM EDT - 3 years ago

AgeX Therapeutics Reports Second Quarter 2022 Financial Results

May 18, 2022, 8:30 AM EDT - 3 years ago

Dr. Joanne Hackett Appointed Chairperson of AgeX Board of Directors

May 16, 2022, 4:00 AM EDT - 3 years ago

Early-Stage Investments for Turkish Metaverse Platform MetaAge Nears $1-Million Mark

May 13, 2022, 4:05 PM EDT - 3 years ago

AgeX Therapeutics Reports First Quarter 2022 Financial Results

Mar 29, 2022, 4:05 PM EDT - 3 years ago

AgeX Therapeutics Reports Fourth Quarter and Annual 2021 Financial Results

littleimagination Jun. 18 at 3:31 PM

$SER Still long SER and Wff, a newer low float Chinese ipo.

0 · Reply

jheerdink Jun. 10 at 6:34 PM

$SER $PFE https://finance.yahoo.com/news/registration-now-open-tribe-public-200500498.html

0 · Reply

jheerdink Jun. 9 at 8:20 PM

0 · Reply

jheerdink Jun. 4 at 6:22 PM

0 · Reply

littleimagination May. 16 at 12:44 PM

$SER Hold on tight to SER. Don't let them steal your shares for under $150.

0 · Reply

littleimagination May. 16 at 12:41 PM

$SER $ 3. dollar gap up. This is the type of stock that could follow RGC to 500!

0 · Reply

jheerdink May. 14 at 3:46 AM

0 · Reply

Stangman88 May. 9 at 11:56 PM

$SER

0 · Reply

jheerdink Apr. 25 at 5:18 PM

0 · Reply

kshonstocks Apr. 24 at 2:48 PM

$SER 200 dma b/o from scans

0 · Reply

Rage_Against_The_Machine Apr. 14 at 8:29 PM

$SER secures $5M via private placement, issuing 962k shares of Series A Preferred at $5.18 (current share price). Funds target Phase 1 trial for SER-252 in Parkinson's. Dilution meets desperation - cash runway extended, but 8% cumulative dividends add pressure. Conversion terms suggest investors want common stock upside without the wait. https://www.sec.gov/Archives/edgar/data/1708599/000170859925000042/ser-20250408.htm

0 · Reply

jheerdink Apr. 9 at 2:41 AM

$SER Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease https://finance.yahoo.com/news/serina-therapeutics-secures-5-million-203000685.html

0 · Reply

DonCorleone77 Apr. 2 at 8:26 PM

$SER Serina Therapeutics files $100M mixed securities shelf

0 · Reply

littleimagination Apr. 2 at 2:27 PM

$SER Is SER the next Nmax? SER has lots of insider buying the past 12 months for some reason. Under 9 million shares. Very tiny float.

0 · Reply

littleimagination Apr. 2 at 2:23 PM

$SER 95,000 insider buy 3/28. SER!

0 · Reply

Lowlow1 Apr. 1 at 6:23 PM

$SER Agmh very good price to jump in at 0.042 has to get to a dollar soon if I post again mybad we are holding over here

0 · Reply

jheerdink Mar. 28 at 3:49 PM

$SER has surged 19.79% to $5.69. Check it out on Yahoo Finance https://finance.yahoo.com/quote/SER?p=SER

0 · Reply

DonCorleone77 Mar. 24 at 11:05 AM

$SER Serina Therapeutics to present on POZ-lipid technology at ACS Spring 2025 Serina Therapeutics announced that Randall Moreadith, CDO, will present new data at the ACS Spring 2025 Meeting and Expo in San Diego, CA. His presentation, titled "A Non-Immunogenic LNP for Gene Delivery: Characterization of Poly(oxazoline) Lipid Nanoparticles," will highlight findings on the immunogenic profile of Serina's proprietary POZ-lipid technology. Dr. Moreadith will share data demonstrating that Serina's POZ-lipid, a key component of lipid nanoparticles, did not trigger an IgM or IgG antibody response following repeat dosing in rats. In contrast, polyethylene glycol-lipid standards, commonly used in current LNP formulations, elicited a strong and boosted antibody response. Anti-PEG antibodies have been implicated as a potential cause of anaphylaxis and other serious adverse events observed in humans receiving PEGylated mRNA vaccines. The absence of an immune response to Serina's POZ-lipid represents a novel discovery that could enable the development of safer and more effective LNP formulations for gene therapy and RNA-based medicines.

0 · Reply

Erikg19 Mar. 19 at 7:56 AM

$APDN $CANF $SER $OPGN

0 · Reply

dln101 Mar. 18 at 10:35 PM

$APDN holding for 100% here 🤔 next $CANF $SER $OPGN 🔥🚀

0 · Reply

JarvisFlow Mar. 11 at 12:30 PM

Jones Trading has updated their rating for Serina Therapeutics ( $SER ) to Buy with a price target of 11.

0 · Reply

jheerdink Mar. 7 at 3:12 AM

$SER

0 · Reply

Market Cap	56.81M
Revenue (ttm)	60,000.00
Net Income (ttm)	-11.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-18,566.67%
Debt to Equity Ratio	0.00

Volume	4,400
Avg Vol	12,778
Day's Range	N/A - N/A
Shares Out	9.97M
Stochastic %K	37%
Beta	0.70
Analysts	Strong Sell
Price Target	$11.00